Vanderbilt University-PET imaging Resource to Enhance Delivery of Individualized Cancer Therapeutics


Vanderbilt's Part

Precision cancer medicine, which seeks to exploit unique cellular, molecular and genetic characteristics of individual tumors to optimize treatment, remains a critically unmet need. Despite advances in biomarker technologies that yield high-quality cellular and genomic data, critical gaps remain to consistently match patients with cancer and ideal therapies. While ‘predictive’ genomic assays based on RNA and DNA are now commonplace, current methods largely ignore tumor phenotypes differentiable by quantitative imaging. The overarching vision for VU-PREDICT is a suite of quantitative imaging tools that facilitate the discovery and optimization of novel, predictive gene expression signatures; such imaging-derived signatures can be deployed by the greater oncology community to improve the personalization of cancer treatment.

VU-PREDICT represents a ‘convergent research’ approach, which crosses disciplinary boundaries and integrates unique tools and knowledge, to improve precision cancer medicine. Our unique expertise in PET imaging, radiochemistry, mouse models, and clinical experience will allow us to develop novel imaging methods that ultimately match patients with precision cancer medicine.

Recent News

25 January 2019

VU-PREDICT Web Portal Live!

Through the work of Dr. Lynne Berry and Karla-Anne Knapp, the VU-PREDICT web portal is live.

01 October 2018

U24 Begins!

U24 funding open

More news